- Home
- AVIR vs MNPR Comparison
AVIR vs MNPR Comparison
Compare AVIR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- MNPR
- Stock Information
- Founded
- AVIR 2012
- MNPR 2014
- Country
- AVIR United States
- MNPR United States
- Employees
- AVIR N/A
- MNPR N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- MNPR Health Care
- Exchange
- AVIR Nasdaq
- MNPR Nasdaq
- Market Cap
- AVIR 273.7M
- MNPR 249.5M
- IPO Year
- AVIR 2020
- MNPR 2019
- Fundamental
- Price
- AVIR $2.97
- MNPR $31.73
- Analyst Decision
- AVIR Hold
- MNPR Strong Buy
- Analyst Count
- AVIR 1
- MNPR 5
- Target Price
- AVIR $6.00
- MNPR $59.50
- AVG Volume (30 Days)
- AVIR 441.1K
- MNPR 18.2K
- Earning Date
- AVIR 05-12-2025
- MNPR 05-13-2025
- Dividend Yield
- AVIR N/A
- MNPR N/A
- EPS Growth
- AVIR N/A
- MNPR N/A
- EPS
- AVIR N/A
- MNPR N/A
- Revenue
- AVIR N/A
- MNPR N/A
- Revenue This Year
- AVIR N/A
- MNPR N/A
- Revenue Next Year
- AVIR N/A
- MNPR N/A
- P/E Ratio
- AVIR N/A
- MNPR N/A
- Revenue Growth
- AVIR N/A
- MNPR N/A
- 52 Week Low
- AVIR $2.46
- MNPR $1.72
- 52 Week High
- AVIR $4.15
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- AVIR 56.05
- MNPR 37.28
- Support Level
- AVIR $2.78
- MNPR $34.02
- Resistance Level
- AVIR $3.03
- MNPR $36.82
- Average True Range (ATR)
- AVIR 0.17
- MNPR 3.54
- MACD
- AVIR 0.03
- MNPR -0.71
- Stochastic Oscillator
- AVIR 88.03
- MNPR 27.91
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.